Key result
High maternal albumin concentrations (21 g/L) resulted in significantly lower placental tissue digoxin concentrations compared to low maternal albumin concentrations (0.45 vs 0.82 ng/mg protein; P<0.05).
Why the study?
Does maternal and fetal albumin concentration influence the transplacental transfer and tissue accumulation of digoxin in isolated human placentae?
Does maternal and fetal albumin concentration influence the transplacental transfer and tissue accumulation of digoxin in isolated human placentae?
Absolute Event Rate: 0.45% vs 0.82%
p-value: p=<0.05
Maternal and fetal serum albumin concentrations influence transplacental digoxin transfer, which may impact the efficacy of transplacental glycoside treatment for fetal cardiac disease.
High maternal albumin may limit placental digoxin accumulation; leaves open whether albumin levels affect transplacental fetal arrhythmia therapy.
The aim of this study was to evaluate the influence of different maternal and fetal albumin concentrations on the transplacental transfer and the placental tissue accumulation of digoxin. Digoxin passage across the isolated lobules of 15 human placentae was calculated from repeated fetal and maternal perfusate samples, and placental tissue digoxin concentrations were measured at the end of the experiments. Metildigoxin (Lanitop) was added to the maternal medium at a concentration of 5.70 +/- 0.73 ng mL-1, and maternal and fetal perfusate albumin (BSA) concentrations were kept equal either at a high concentration of 21 g L-1 (Group I; n = 5) or at a low concentration of 3 g L-1 (Group III; n = 5), or differed with a materno-fetal gradient of 21:3 g L-1 (Group II; n = 5). In the experiments with low maternal albumin concentrations (Group III), digoxin concentrations in the maternal circuit decreased to 3.56 ng mL-1, whereas digoxin concentrations in the fetal circuit reached 2.59 ng mL-1 over a 3-h period. With maternal BSA concentrations of 21 g L-1 (Group I and Group II), the decrease in digoxin concentration in the maternal circuit was lower (P < 0.05), and digoxin tissue concentrations at the end of the experiments were smaller (0.45 +/- 0.07 and 0.42 +/- 0.03 v. 0.82 +/- 0.32 ng mg-1 protein, Group I and Group II v. Group III respectively; P < 0.05). Comparing only those lobules with similar high concentrations of maternal protein, fetal BSA concentrations of 21 g L-1 resulted in a greater increase in digoxin concentrations in the fetal circuit (end-feto to initial-maternal digoxin concentrations of 0.44 +/- 0.08 v. 0.37 +/- 0.04 ng mg-1 protein (Group I v. Group II respectively), although this was not significant. The data suggest that maternal and fetal serum albumin concentrations may have an influence on transplacental digoxin transfer, and this should be considered when treating fetuses with cardiac disease transplacentally with glycosides.
No takes yet. Share an insight, caveat, or question.
Schmolling et al. (1996) studied this question. High maternal albumin (BSA) concentration vs. Low maternal albumin concentration (3 g L-1) was evaluated on Placental tissue digoxin concentrations at the end of the experiments (p=<0.05). High maternal albumin concentrations (21 g/L) resulted in significantly lower placental tissue digoxin concentrations compared to low maternal albumin concentrations (0.45 vs 0.82 ng/mg protein; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: